Product Images Revlimid

This is medication information for Revlimid capsules with a strength of 5mg, indicated as prescription only. The National Drug Code for this product is 59572-405-28. The text contains a warning about the potential risks for human use. Some of the text is unreadable due to errors.*

This is a medication called Revlimid in its 10mg capsule form. The packaging contains 28 capsules and has a National Drug Code (NDC) of 59572-410-28. It also includes a lot number of s20625, an expiration date of e77 and a street number of 1790C. The last few lines of text are not legible.*

Revlimid (lenalidomide) is a prescription drug available in capsule form with a strength of 15mg. The NDC code for the drug is 50572-415-21. However, the rest of the text appears to be gibberish and cannot be understood.*

This appears to be the results of a medical study, comparing the efficacy of Lenalidomide and a placebo for progression-free survival. The study found that Lenalidomide had a lower hazard ratio for progression-free survival and a higher median duration of progression-free survival compared to the placebo group. It also includes a graph showing the progression-free survival over time for both groups and the number of subjects at risk.*

This is a medical report including findings of the clinical trial of Lenalidomide for Progression-free Survival (PFS) in patients with a medical condition not mentioned in the report. The text includes numerical values of median response rate and percentage for the treatment group and placebo group and the number of subjects at risk.*

The text appears to be a graph or chart showing the proportion of subjects over time in months, with a decrease in the number of subjects and a corresponding decrease in the hazard ratio (HR). The log rank p-value is less than 0.001. However, without more context or information, it is difficult to provide a more specific description.*

This text appears to be a statistical analysis related to medical research, probably a clinical trial. It includes the proportion of subjects, HR value with confidence intervals, p-value, and the name of treatments (RevimidiDex and PlaceborDex) with some data related to them, such as sample size and time to progression in months.*